Market Place
Sourcing Support
Regulus to Present at Oppenheimer Annual Healthcare Conference
04 Feb 2025 //
PR NEWSWIRE
Regulus Reports Positive Updates On ADPKD Drug Farabursen
29 Jan 2025 //
PR NEWSWIRE
Regulus Announces Participation at Upcoming Investment Conference
26 Nov 2024 //
PR NEWSWIRE
Regulus Reports Q3 2024 Financials & Updates
07 Nov 2024 //
PR NEWSWIRE
Regulus Announces Enrollment Ph1b for Polycystic Kidney Disease
08 Oct 2024 //
PR NEWSWIRE
Regulus Therapeutics To Participate In Two Investment Conferences
28 Aug 2024 //
PR NEWSWIRE
Regulus Therapeutics Reports Q2 2024 Results And Recent Updates
08 Aug 2024 //
PR NEWSWIRE
Regulus Therapeutics To Present At Canaccord Genuity Conference
06 Aug 2024 //
PR NEWSWIRE
Regulus Therapeutics To Participate In Healthcare Investment Conferences
09 Jul 2024 //
PR NEWSWIRE
Regulus Therapeutics Announces Positive Data From Phase 1b MAD Trial Of RGLS8429
24 Jun 2024 //
PR NEWSWIRE
Regulus Promotes Rekha Garg To Chief Medical Officer
16 May 2024 //
PR NEWSWIRE
Regulus Therapeutics Names New Chief Medical Officer
16 May 2024 //
CONTRACT PHARMA
Regulus Therapeutics Q1 2024 Financials, Updates
09 May 2024 //
PR NEWSWIRE
Regulus Therapeutics Advances to Cohort 4 of Phase 1b MAD Clinical Trial
06 May 2024 //
PR NEWSWIRE
Regulus To Join Canaccord Genetic Medicine Webcast
30 Apr 2024 //
PR NEWSWIRE
Regulus Therapeutics Reports Q4 and Year-End 2023 Financial Results a
21 Mar 2024 //
PR NEWSWIRE
Regulus Therapeutics Announces Positive Data from Phase 1b Trial of RGLS8429
12 Mar 2024 //
PR NEWSWIRE
Regulus Therapeutics Announces Completion of Enrollment in MAD Trial of RGLS8429
02 Jan 2024 //
PR NEWSWIRE
Regulus Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Regulus Announces First Patient Dosed in Third Cohort of Phase 1b of RGLS8429
02 Nov 2023 //
PR NEWSWIRE
Regulus Therapeutics Advances to Cohort 3 of Phase 1b MAD Trial of RGLS8429
19 Oct 2023 //
PR NEWSWIRE
Regulus Announces Positive Data from Phase 1bTrial of RGLS8429
20 Sep 2023 //
PR NEWSWIRE
Regulus Announces Completion of Enrollment in Phase 1b Trial of RGLS8429
13 Sep 2023 //
PR NEWSWIRE
Regulus Announces Participation at Two Healthcare Investment Conferences
05 Sep 2023 //
PR NEWSWIRE
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
23 Aug 2023 //
PR NEWSWIRE
Regulus Reports Second Quarter 2023 Financial Results and Recent Updates
08 Aug 2023 //
PR NEWSWIRE
Regulus to Present at the Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
PR NEWSWIRE
Regulus Therapeutics to Present at H.C. Wainwright 2nd Annual Kidney Conference
18 Jul 2023 //
PR NEWSWIRE
Regulus Announces 1st Patient Dosed 2nd Cohort of Ph1b (MAD) Trial of RGLS8429
27 Jun 2023 //
PR NEWSWIRE
Regulus Announces Appointment of Preston S. Klassen, M.D. to its BOD
23 Jun 2023 //
PR NEWSWIRE
Regulus Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis
20 Jun 2023 //
PR NEWSWIRE
Regulus Therapeutics Strengthens Research & Development Leadership
12 Jun 2023 //
PR NEWSWIRE
Regulus Therapeutics Advances to Cohort 2 of Ph 1b Multiple-Ascending Dose (MAD)
16 May 2023 //
PR NEWSWIRE
Regulus Therapeutics Reports 1Q 2023 Financial Results and Recent Updates
11 May 2023 //
PR NEWSWIRE
Regulus Therapeutics Announces $15 Million Private Placement of Equity
13 Apr 2023 //
PR NEWSWIRE
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
23 Mar 2023 //
PR NEWSWIRE
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13 Jan 2023 //
PR NEWSWIRE
Regulus Therapeutics Reports Third Quarter 2022 FYR and Recent Updates
10 Nov 2022 //
PRNEWSWIRE
Regulus Announces Timing for Third Quarter 2022 Financial Results Webcast
03 Nov 2022 //
PRNEWSWIRE
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
27 Oct 2022 //
GALVNEWS
Regulus Announces Positive Safety and PK Data from the PI SAD Trial of RGLS8429
12 Sep 2022 //
PRNEWSWIRE
Regulus Therapeutics to Participate in Upcoming Investor Conferences
02 Sep 2022 //
PRNEWSWIRE
Regulus Therapeutics Reports Q2 2022 Rusult and Recent Updates
11 Aug 2022 //
PRNEWSWIRE
Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Sanofi walks away from Regulus` kidney disease therapy
19 Jul 2022 //
FIERCEBIOTECH
Regulus Tx Announces Receipt of FDA ODD for RGLS8429 in ADPKD
21 Jun 2022 //
PRNEWSWIRE
Regulus Tx Announces Begins Dosing in PI SAD Trial of RGLS8429 for ADPKD
13 Jun 2022 //
PRNEWSWIRE
Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
02 Jun 2022 //
PRNEWSWIRE
Regulus Therapeutics to Present at the H.C. Wainwright Conference
17 May 2022 //
PRNEWSWIRE
Regulus Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Regulus Tx Announces FDA Acceptance of IND Application for RGLS8429
11 May 2022 //
PRNEWSWIRE
Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Regulus Tx Initiates Preclinical Studies in ALS; Collaborates with BHW
24 Mar 2022 //
PRNEWSWIRE
Regulus Tx Reports Q4 and Year-End 2021 Financial Results and Recent Updates
10 Mar 2022 //
PRNEWSWIRE
Regulus Therapeutics Announces Timing for Q4 and Year-End 2021 Financial Results
03 Mar 2022 //
PRNEWSWIRE
Regulus Completes Enrollment in Phase 2 Trial of Lademirsen for Alport Syndrome
24 Feb 2022 //
PRNEWSWIRE
Regulus Therapeutics to Present at the 11th Annual SVB Leerink Conference
10 Feb 2022 //
PRNEWSWIRE
Regulus Successfully Completes Pre-IND Meeting with FDA for RGLS8429
20 Jan 2022 //
PRNEWSWIRE
Regulus Therapeutics Announces Private Placement of Equity
24 Nov 2021 //
PRNEWSWIRE
Regulus Reports Q3 2021 Financial Results and Recent Updates
10 Nov 2021 //
PRNEWSWIRE
